TABLE 3.
Baseline parameters in patients receiving ACE‐inhibitors but no ARB for different PP quartiles
| PP < 47.0 mmHg | PP 47.0 ‐ 60.0 mmHg | PP 60.0 ‐ 73.4 mmHg | PP > 73.4 mmHg | |||
|---|---|---|---|---|---|---|
| Variable | (N = 432) | (N = 432) | (N = 426) | (N = 427) | P* | P. linear** |
| Age (years) | 58.5(10.4) | 62.9( 10 ) | 65.8(8.37) | 68.5(7.84) | <0.001 | <0.001 |
| Female sex (%) | 24.5 | 26.4 | 28.4 | 34 | 0.015 | 0.002 |
| BMI (kg/m2) | 27.5(4.24) | 27.7(4.61) | 28.1(4.22) | 27.9(4.19) | 0.131 | 0.131 |
| LDL‐C (mg/dl) | 114(34.8) | 114(31.4) | 114(32.3) | 116(34.9) | 0.286 | 0.286 |
| HDL‐C (mg/dl) | 35.5(9.45) | 37.5(10.1) | 37.8(10.6) | 39.4(11.3) | <0.001 | <0.001 |
| TG (mg/dl) | 144(112‐202) | 144(113‐190) | 157(114‐205) | 146(108‐198) | 0.508 | 0.508 |
| SBP (mmHg) | 115(12.9) | 134(12.2) | 150(12.5) | 171(16) | <0.001 | <0.001 |
| DBP (mmHg) | 76.7(11) | 80.5(11.3) | 83.7(11.4) | 84.6(11.9) | <0.001 | <0.001 |
| Creatinine | 0.982(0.232) | 0.972(0.222) | 0.981(0.245) | 1.01(0.337) | 0.079 | 0.079 |
| Cystatin C | 1.01(0.403) | 0.997(0.278) | 1(0.287) | 1.12(0.512) | <0.001 | <0.001 |
| Uromodulin | 158(71.9) | 157(70.9) | 141(63) | 137(71.9) | <0.001 | <0.001 |
| Central PP | 55.6(17.5) | 65.6(18.7) | 74.6(19) | 87.4(19.8) | <0.001 | <0.001 |
| PP | 38.5(5.98) | 53.6(3.69) | 66.5(3.86) | 86.8(11.1) | <0.001 | <0.001 |
| DP | 7990(1700) | 9270(1930) | 10300(2030) | 11700(2470) | <0.001 | <0.001 |
| MAP | 89.6(11.3) | 98.4(11.5) | 106(11.7) | 114(12.3) | <0.001 | <0.001 |
| Renin (pg/ml) | 22.8(8.98‐51.3) | 15(6.59‐33.5) | 12(6.59‐27.5) | 11.4(5.99‐24) | <0.001 | <0.001 |
| Aldosterone (ng/l) | 69(43‐120) | 73(43‐112) | 72.5(46‐115) | 79(47‐120) | 0.234 | 0.234 |
| Angiotensinogen (nnmol/l) | 1060(740‐1360) | 1100(830‐1390) | 1200(906‐1510) | 1170(905‐1450) | <0.001 | <0.001 |
| Angiotensin‐I (ng/l) | 1380(960‐1770) | 1420(1080‐1810) | 1550(1170‐1960) | 1520(1170‐1880) | <0.001 | <0.001 |
| Angiotensin‐II (ng/l) | 23(14‐44) | 20(11‐35) | 20(13‐37) | 18(11‐33) | 0.001 | 0.001 |
| ACE (U/l) | 15(8‐28) | 15(8‐30) | 14(8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26) | 14(8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25) | 0.022 | 0.022 |
| Adrenalin (ng/l) | 32(20‐50) | 33(21‐55) | 35(23‐56) | 35(24‐59.8) | 0.005 | 0.005 |
| Noradrenalin (ng/l) | 306(208‐444) | 310(214‐453) | 329(230‐459) | 324(219‐470) | 0.129 | 0.129 |
| Aldosterone / Renin | 1.71(0.782‐3.94) | 2.94(1.12‐6.2) | 3.24(1.51‐6.75) | 3.76(1.43‐8.14) | <0.001 | <0.001 |
| NT‐proBNP (pg/mL) | 456(170‐1390) | 397(130‐1100) | 415(152‐1000) | 498(213‐1400) | 0.285 | 0.284 |
| Coronary artery disease (%) | 82.4 | 84.5 | 84.5 | 89.7 | 0.020 | 0.004 |
| Diabetes mellitus (%) | 37 | 38.7 | 45.8 | 54.8 | <0.001 | <0.001 |
| Smoking (current or ex, %) | 72.5 | 69 | 62.7 | 63.9 | 0.007 | 0.002 |
*ANOVA for continuous variables, non‐normally distributed variables were log‐transformed before entering analyses, and chi‐square test for categorical variables; ** Linear trend, for categorical variable the Cochrane‐Armitage test was used.
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; DP, double product; MAP, mean arterial pressure; ACE, angiotensin Converting Enzyme, CAD: Coronary artery disease.